Harrow (HROW) vs Nanobiotix S.A. (NBTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nanobiotix S.A. (NBTX) has outperformed Harrow (HROW) over the past year, gaining 17.4% versus a loss of 26.9%. Over five years, HROW leads with a +209.6% price change compared with +92.0% for NBTX. Nanobiotix S.A. is the larger company by market cap ($1.25 billion vs $1.15 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HROW | NBTX |
|---|---|---|
| Share price | $30.62 | $24.62 |
| Market cap | $1.15B | $1.25B |
| 1-day change | +0.89% | -2.42% |
| YTD return | -37.51% | +6.49% |
| 1-year return | -26.92% | +17.41% |
| 5-year return | +209.61% | +92.04% |
| Forward P/E | 11.04 | — |
| EPS (TTM) | $-0.99 | $-1.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $54.85 | $57.14 |
| 52-week low | $28.54 | $14.78 |
| Distance from 52-week high | -44.18% | -56.91% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +112.28% | +118.85% |
| Average volume | 552.72K | 149.07K |
| Shares outstanding | 37.49M | 50.92M |
| Employees | 373 | 100 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NBTX has outperformed HROW by 44.3 percentage points over the past year.
About Harrow
HROW stock →Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments.
Healthcare · Drug Manufacturers - Specialty & Generic · 373 employees
About Nanobiotix S.A.
NBTX stock →Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
Healthcare · Biotechnology · 100 employees
HROW vs NBTX FAQ
Which is bigger, Harrow or Nanobiotix S.A.?
Nanobiotix S.A. (NBTX) is larger, with a market capitalization of $1.25B compared with $1.15B for Harrow (HROW).
Which stock has performed better over the past year, HROW or NBTX?
NBTX returned +17.41% over the past 12 months, compared with -26.92% for HROW (price return, excluding dividends). Past performance does not predict future results.
Are Harrow and Nanobiotix S.A. in the same industry?
Both are in the Healthcare sector, but in different industries: Drug Manufacturers - Specialty & Generic for Harrow and Biotechnology for Nanobiotix S.A..